FACULTY CHAIRS & PRESENTERS
Stacey A. Cohen, MD
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Associate Professor, Division of Hematology and Oncology
University of Washington
Seattle, Washington
Antonia R. Sepulveda, MD, PhD, FACP
Professor and Chair, Department of Pathology
Ralph E. Loewy Professor of Oncology
GW Cancer Center
George Washington University School of Medicine and Health Sciences
Washington, District of Columbia
PROGRAM OVERVIEW
This program addresses the importance of comprehensive molecular testing in metastatic colorectal cancer (mCRC) and outlines recent updates in clinical practice guideline recommendations for various molecular tests in mCRC. The program aims to bridge the gap in awareness of clinical trial data for approved targeted and immunotherapies for mCRC, as well as building knowledge of clinical trials that are currently assessing approved second-line treatments in the first-line setting. Additionally, the program is designed to increase awareness of pros and cons for different types of molecular testing available, including their associated sample requirements. Further program focus targets development of individual test strategies and the appreciation of individual practitioner roles as part of a molecular tumor board (MTB).
TARGET AUDIENCE
This educational activity is specifically designed for community oncologists, oncology nurses, and nurse practitioners.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recall clinical practice guideline recommendations for comprehensive molecular testing in mCRC
- Apply understanding of the key clinical trial efficacy and safety data for recently approved targeted therapies and immunotherapies into clinical practice for mCRC, and summarize the emerging evidence for their use in earlier treatment settings
- Describe molecular testing strategies for mCRC and the role of the molecular tumor board (MTB) in interpreting test results
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Stacey A. Cohen, MD | Consulting fees: Janssen, DoMore Diagnostics, GlaxoSmithKline, Incyte, Exact Sciences, Merck & Co., AbbVie, Pfizer, Agenus, Guardant Health Contracted research: BioNTech, Biomea Fusion, Pfizer, Tempus, Natera, BillionToOne |
| Antonia R. Sepulveda, MD | Consulting fees: Johnson & Johnson, the Association of Cancer Care Centers (ACCC), DoMore Diagnostics Provided education: The France Foundation, OncLive, PRIME |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Program Director for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 09, 2025
EXPIRATION DATE: July 09, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY CHAIRS & PRESENTERS
Stacey A. Cohen, MD
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Associate Professor, Division of Hematology and Oncology
University of Washington
Seattle, Washington
Antonia R. Sepulveda, MD, PhD, FACP
Professor and Chair, Department of Pathology
Ralph E. Loewy Professor of Oncology
GW Cancer Center
George Washington University School of Medicine and Health Sciences
Washington, District of Columbia
PROGRAM OVERVIEW
This program explores the importance and feasibility of comprehensive molecular testing in accordance with NCCN guidelines, particularly as certain second-line treatments transition to first line therapies. It also provides practical strategies for effective testing and highlights the role of molecular tumor boards (MTB) in optimizing treatment planning.
TARGET AUDIENCE
This educational activity is specifically designed for community oncologists, oncology nurses, and nurse practitioners.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recall clinical practice guideline recommendations for comprehensive molecular testing in mCRC
- Describe molecular testing strategies for mCRC and the role of the molecular tumor board (MTB) in interpreting test results
ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Stacey A. Cohen, MD | Consulting fees: Janssen, DoMore Diagnostics, GlaxoSmithKline, Incyte, Exact Sciences, Merck & Co., AbbVie, Pfizer, Agenus, Guardant Health Contracted research: BioNTech, Biomea Fusion, Pfizer, Tempus, Natera, BillionToOne |
| Antonia R. Sepulveda, MD | Consulting fees: Johnson & Johnson, the Association of Cancer Care Centers (ACCC), DoMore Diagnostics Provided education: The France Foundation, OncLive, PRIME |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Program Director for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected].
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/.
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected].
Please listen to the podcast below:
RELEASED DATE: July 09, 2025
EXPIRATION DATE: July 09, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY CHAIRS & PRESENTERS
Stacey A. Cohen, MD
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Associate Professor, Division of Hematology and Oncology
University of Washington
Seattle, Washington
Antonia R. Sepulveda, MD, PhD, FACP
Professor and Chair, Department of Pathology
Ralph E. Loewy Professor of Oncology
GW Cancer Center
George Washington University School of Medicine and Health Sciences
Washington, District of Columbia
PROGRAM OVERVIEW
This program examines key clinical efficacy and safety data for recently approved targeted therapies and immunotherapies, with a focus on emerging evidence supporting their use in earlier treatment settings.
TARGET AUDIENCE
This educational activity is specifically designed for community oncologists, oncology nurses, and nurse practitioners.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply understanding of the key clinical trial efficacy and safety data for recently approved targeted therapies and immunotherapies into clinical practice for mCRC, and summarize the emerging evidence for their use in earlier treatment settings
ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Stacey A. Cohen, MD | Consulting fees: Janssen, DoMore Diagnostics, GlaxoSmithKline, Incyte, Exact Sciences, Merck & Co., AbbVie, Pfizer, Agenus, Guardant Health Contracted research: BioNTech, Biomea Fusion, Pfizer, Tempus, Natera, BillionToOne |
| Antonia R. Sepulveda, MD | Consulting fees: Johnson & Johnson, the Association of Cancer Care Centers (ACCC), DoMore Diagnostics Provided education: The France Foundation, OncLive, PRIME |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Program Director for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected].
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/.
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected].
Please listen to the podcast below:
RELEASED DATE: July 09, 2025
EXPIRATION DATE: July 09, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
